[A case of recurrent breast cancer responding to long-term administration of tamoxifen]. - Suppr | 超能文献

[A case of recurrent breast cancer responding to long-term administration of tamoxifen].

作者信息

Yayoi E, Kobayashi T, Inaji H, Maeura Y, Mori T

出版信息

Gan To Kagaku Ryoho. 1984 Aug;11(8):1683-6.

Abstract

A 44-year-old premenopausal woman with metastatic breast cancer to the bones was treated with tamoxifen and tegafur followed by a minimal dose of tamoxifen alone, with complete response for more than 90 months. Initially, tamoxifen was given with a dose of 20 mg daily in combination with 600 mg daily of tegafur for 22 months, a remission of low back pain and recalcification of the lytic lesion in the pelvis. After reduction of tamoxifen dose to 10 mg/daily and withdrawal of tegafur, regression of the disease continued for another 68+ months. Bone metastasis completely disappeared, and the patient is still in remission. No significant side effects from tamoxifen were encountered. Tamoxifen appears to be a useful and safe treatment for recurrent breast cancer.

摘要

相似文献

1

[A case of recurrent breast cancer responding to long-term administration of tamoxifen].

Gan To Kagaku Ryoho. 1984 Aug;11(8):1683-6.

2

[A patient with hepatic metastasis of breast cancer successfully treated with combined chemoendocrine therapy using epirubicin, tegafur and tamoxifen].[1例乳腺癌肝转移患者采用表柔比星、替加氟和他莫昔芬联合化疗内分泌治疗成功治愈]

Gan To Kagaku Ryoho. 1999 Sep;26(10):1475-8.

3

[Response to rechallenged tamoxifen of metastatic breast cancer relapsed after surgical adjuvant tamoxifen treatment].[他莫昔芬辅助治疗后复发的转移性乳腺癌再次接受他莫昔芬治疗的反应]

Gan To Kagaku Ryoho. 1991 Jul;18(8):1333-6.

4

Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: why, who and how long?他莫昔芬治疗后使用芳香化酶抑制剂（来曲唑）进行延长疗程的乳腺癌治疗：为何、针对何人以及持续多久？

Eur J Obstet Gynecol Reprod Biol. 2006 Jun 1;126(2):146-54. doi: 10.1016/j.ejogrb.2006.03.006. Epub 2006 Apr 18.

5

[A case of breast cancer with multiple metastases successfully treated by medroxyprogesterone acetate with intermittent intra-arterial infusion low-dose chemotherapy to hepatic metastasis].

Gan To Kagaku Ryoho. 2000 Dec;27(14):2243-7.

6

[Clinical evaluation of NK 622 (toremifene citrate) in advanced or recurrent breast cancer--a comparative study by a double blind method with tamoxifen].NK 622（枸橼酸托瑞米芬）治疗晚期或复发性乳腺癌的临床评估——与他莫昔芬的双盲法对比研究

Gan To Kagaku Ryoho. 1993 Feb;20(2):247-58.

7

[Efficacy of combination therapy consisting of cyclophosphamide, adriamycin, UFT and oophorectomy/tamoxifen for advanced or recurrent breast cancer].

Gan To Kagaku Ryoho. 1994 Oct;21(14):2445-52.

8

Predictive implications of nucleoside metabolizing enzymes in premenopausal women with node-positive primary breast cancer who were randomly assigned to receive tamoxifen alone or tamoxifen plus tegafur-uracil as adjuvant therapy.核苷代谢酶对绝经前淋巴结阳性原发性乳腺癌患者的预测意义，这些患者被随机分配接受单纯他莫昔芬或他莫昔芬加替加氟-尿嘧啶作为辅助治疗。

Int J Oncol. 2007 Oct;31(4):899-906.

9

[UFT-MT therapy in advanced or recurrent breast cancer].[优福定-甲硫氨酸治疗晚期或复发性乳腺癌]

Gan To Kagaku Ryoho. 1990 Dec;17(12):2437-41.

10

[A case of advanced breast cancer effectively treated with tamoxifen].[他莫昔芬有效治疗晚期乳腺癌一例]

Gan To Kagaku Ryoho. 1992 Aug;19(9):1391-4.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。